NCT06204991View on ClinicalTrials.gov

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

March 1, 2027

Study Completion Date

April 1, 2028

Conditions
Melanoma Stage IIIMelanoma Stage IVMelanoma
Interventions
BIOLOGICAL

ADP-TILIL7

Autologous tumor infiltrating lymphocytes genemodified (by a lentiviral vector) to produce IL-7 upon antigen engagement

DRUG

Cyclophosphamide

Lymphodepleting Chemotherapy

DRUG

Fludarabine Phosphate

Lymphodepleting Chemotherapy

DRUG

Proleukin

IL-2

Trial Locations (2)

2730

RECRUITING

Department of Oncology, Herlev

RECRUITING

Department of Oncology, Herlev

Sponsors

Collaborators (1)

Adaptimmune
All Listed Sponsors
collaborator

Adaptimmune

INDUSTRY

lead

Inge Marie Svane

OTHER

NCT06204991 - To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma | Biotech Hunter | Biotech Hunter